The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2023 | Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, shares some updates from the POLLUX trial (NCT02076009), which is comparing the efficacy of daratumumab in combination with lenalidomide and dexamethasone (DRd) to lenalidomide and dexamethasone (Rd) in patients with relapsed/refractory (R/R) multiple myeloma. This trial has recently demonstrated an improvement in overall survival (OS) in patients treated with DRd. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
